Skip to main content

Table 1 Number of subjects by study and dose.

From: Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder

  Placebo Fesoterodine 4 mg Fesoterodine 8 mg Fesoterodine 12 mg Total
Phase II      
   Cole, 2004 [7] 183 186 172 186 727
   Nitti et al, 2006 [8] 43 44 47 39 173
Phase III      
   Chapple et al, 2007 [3] 277 263 276 0 816
   Nitti et al, 2007 [2] 265 266 267 0 798
Total 768 759 762 225 2514